SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (181)3/6/2002 12:35:37 PM
From: rkrw  Read Replies (1) of 508
 
A nice hatchet job.

This is a continuation of rumors spread last year that itmn was going to get an fda marketing warning---which proved to be false. I guess since that didn't happen, they can publish this through their shill and see if that stirs things.

<<<It can't wait until 2003, which is the earliest planned approval for Actimmune as an IPF treatment.>>>

2003, a long time to wait :-)

The phase III results are due in all of 8 months. If the trial is successful and the fda agrees, a potential IPF approval could be roughly 14 months away, so this could be rendered moot in short order.

Feuerstein doesn't understand off label promotion rules. Even with a warning, all that would mean is itmn would have to change certain practices or actions the FDA objected to. It would not mean they would be required to cease efforts as implied. His Celgene example is a case in point but he failed to disclose the warning was just that and they continue to promote via education and referencing published data.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News